AVNR

This post was just published on ZYX Short Change Alert. The Phase II for AVP-923 results are positive.  Almost every such drug with positive Phase II results has failed in Phase III.  However, in the short-term the stock will run and has hit the mental stop if still holding. The upper

  This post was just published on ZYX Short Change Alert. The stock is running up on a patent win. The big move is not justified. Consider shorting up to 25% in tranches in the zone of  $4.70-6.30. Mental stop over $7.33. Target $3.50- 4.11.  The stock is at $4.77 as